Lumicitabine

Drug Profile

Lumicitabine

Alternative Names: AL 8176; ALS 008176; ALS-8176; JNJ-1575; JNJ-64041575

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen Research & Development
  • Class Antivirals; Furans; Nucleosides; Pyrimidines
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections
  • Preclinical Metapneumovirus infections; Parainfluenza virus infections

Most Recent Events

  • 28 Jun 2017 Janssen initiates enrolment in a phase I pharmacokinetic trial in Germany (NCT03189498)
  • 21 Jun 2017 Janssen plans a pharmacokinetic phase I trial in Germany (NCT03189498)
  • 16 Jun 2017 Janssen completes a phase I trial in Respiratory syncytial virus infections (In volunteers) in Germany (NCT03105986)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top